Answers are grounded in this paper and cite their sources.
Mibefradil represents a new class of calcium channel blockers (T-type) with a favorable hemodynamic and side-effect profile compared to traditional agents.
Calcium antagonists Calcium antagonists are potent vasodilators and are widely used in the treatment of hypertension and angina pectoris. The currently available compounds belong to three classes: (1) dihydropyridines (e.g. nifedipine, amlodipine, felodipine), (2) phenylalkylamines (e.g. verapamil) and (3) benzothiazepines (e.g. diltiazem). The three classes differ in their pharmacological profile and safety. For example, verapamil and diltiazem lower heart rate, while dihydropyridines increase it or leave it unchanged. With most of the latter compounds a marked activation of the sympathetic nervous system has been noted. Most compounds exhibit negative inotropic effects, particularly the first-generation molecules, which is disadvantageous in patients with impaired left ventricular function. The most common side effects of these drugs are flushing, headache and edema. With verapamil, constipation may represent a problem in certain patients. Hence, in spite of the large number of calcium antagonists that are available, there is a need for new compounds with greater efficacy and improved tolerability. A new compound should lack any negative inotropism, avoid any increase in sympathetic outflow or heart rate and exhibit a high degree of vascular selectivity. Furthermore, a low incidence of side effects, particularly ankle edema, and optimal pharmacokinetics allowing a single daily dose are desirable. Properties of mibefradil Mibefradil is a new calcium antagonist with promising pharmacological and clinical properties. It is a potent direct vasodilator, elicits endothelium-dependent relaxation and facilitates the effects of nitric oxide in vascular smooth muscle. The drug is a particularly efficacious vasodilator in intramyocardial coronary arteries, which may be important for its anti-ischemic effects and for the lack of steal in the coronary circulation. Furthermore, mibefradil has antiproliferative properties in human vascular smooth muscle cells in culture. As a unique property, mibefradil blocks transient (T-type) calcium channels and hence represents a new class of calcium channel blockers. The compound has a high bioavailability, lacks negative inotropic effects at therapeutic concentrations, does not exhibit reflex tachycardia during vasodilation and actually slightly decreases heart rate. In patients with hypertension, mibefradil has a high efficacy in controlling blood pressure. The drug does not cause constipation and has a low incidence of ankle edema. Large trials are under way to further delineate the properties of this new calcium antagonist in patients with coronary artery disease and/or heart failure.
No takes yet. Share an insight, caveat, or question.
Lüscher et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: